Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.
Schubert ML, Bethge WA, Ayuk FA, von Bonin M, Vucinic V, Wagner-Drouet EM, Subklewe M, Baldus CD, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp MS, Wulf G, Kröger N, Dreger P.
Schubert ML, et al. Among authors: kroger n.
Blood Adv. 2023 Oct 24;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203.
Blood Adv. 2023.
PMID: 37603595
Free PMC article.
No abstract available.